171 related articles for article (PubMed ID: 11464141)
1. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
Ruiz L; Negredo E; Domingo P; Paredes R; Francia E; Balagué M; Gel S; Bonjoch A; Fumaz CR; Johnston S; Romeu J; Lange J; Clotet B;
J Acquir Immune Defic Syndr; 2001 Jul; 27(3):229-36. PubMed ID: 11464141
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
3. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
Martínez E; Conget I; Lozano L; Casamitjana R; Gatell JM
AIDS; 1999 May; 13(7):805-10. PubMed ID: 10357379
[TBL] [Abstract][Full Text] [Related]
4. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
[TBL] [Abstract][Full Text] [Related]
5. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
[TBL] [Abstract][Full Text] [Related]
6. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Carr A; Hudson J; Chuah J; Mallal S; Law M; Hoy J; Doong N; French M; Smith D; Cooper DA;
AIDS; 2001 Sep; 15(14):1811-22. PubMed ID: 11579243
[TBL] [Abstract][Full Text] [Related]
7. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
8. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
Negredo E; Ribalta J; Paredes R; Ferré R; Sirera G; Ruiz L; Salazar J; Reiss P; Masana L; Clotet B
AIDS; 2002 Jul; 16(10):1383-9. PubMed ID: 12131215
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.
Masquelier B; Neau D; Chêne G; Larbère J; Birac V; Ragnaud JM; Fleury HJ
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):309-12. PubMed ID: 11707665
[TBL] [Abstract][Full Text] [Related]
10. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
Tebas P; Yarasheski K; Henry K; Claxton S; Kane E; Bordenave B; Klebert M; Powderly WG
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):589-94. PubMed ID: 15242534
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Negredo E; Moltó J; Muñoz-Moreno JA; Pedrol E; Ribera E; Viciana P; Galindos MJ; Miralles C; Burger D; Rodriguez Fumaz C; Puig J; Gel S; Rodríguez E; Videla S; Ruiz L; Clotet B
Antivir Ther; 2004 Jun; 9(3):335-42. PubMed ID: 15259896
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
[TBL] [Abstract][Full Text] [Related]
15. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
16. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
Easterbrook PJ; Newson R; Ives N; Pereira S; Moyle G; Gazzard BG
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):350-64. PubMed ID: 11468423
[TBL] [Abstract][Full Text] [Related]
17. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
Manfredi R; Calza L; Chiodo F
J Acquir Immune Defic Syndr; 2004 Apr; 35(5):492-502. PubMed ID: 15021314
[TBL] [Abstract][Full Text] [Related]
18. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
[TBL] [Abstract][Full Text] [Related]
20. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
